Stereotaxis Inc

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stereotaxis anticipates revenue growth in 2023 with key innovations

Stereotaxis is poised for growth with key innovations nearing commercialization and a strong balance sheet.
Strategic collaborations, improved pipeline visibility, and targeted growth strategies position the company for future success.
Challenges in customer engagement and market penetration require proactive strategies to drive revenue growth.
Opportunities in SaaS business spin-off, IDN engagement, and product launches offer avenues for revenue expansion and market presence.

Stereotaxis Inc reports revenue decline but expects growth opportunities

Stereotaxis Inc reports revenue decline but expects growth with Genesis
Positive feedback on technology, regulatory progress, and innovation efforts
Challenges include catheter shortages and financial balancing act
Opportunities lie in increasing system orders and upcoming market releases

Stereotaxis Inc reports robust revenue growth and strategic collaborations

Stereotaxis Inc's Q2 2023 performance showcased strong revenue growth and strategic collaborations driving innovation.
While facing challenges like regulatory delays and cash flow issues, the company is focused on reducing cash usage and advancing key projects.
Opportunities lie in connectivity software releases, product development, and regulatory submissions, positioning Stereotaxis for future growth.

Stereotaxis reports Q3 revenue growth, faces operational challenges

Stereotaxis Inc saw modest revenue growth in Q3 driven by robotic system sales, but faced an operating loss.
Maintaining a strong financial position with no debt provides stability amidst operational challenges.
The company's focus on innovation and market strategies presents opportunities for future growth and product development.

Stereotaxis Inc reports Q4 revenue of $4.6M, focuses on innovation and regulatory progress

Stereotaxis Inc navigated challenges in Q4 2023 with a focus on innovation and strategic transformation. Strong financial position and confidence in regulatory processes position the company well for future growth. Revenue guidance for 2024 indicates potential for stable recurring revenue and increased system revenue.

Stereotaxis reports Q1 revenue growth, innovation progress, and APT acquisition

Stereotaxis Inc's Q1 2024 earnings call highlighted revenue growth, innovation progress, and the acquisition of APT. Despite challenges with recurring revenue and an operating loss, the company is optimistic about future growth driven by system backlog and new orders.

Stereotaxis Inc. reports Q2 loss, anticipates growth from GenesisX shipments

Stereotaxis Inc. faces challenges from reduced capital revenue but shows resilience with stable recurring revenue and a strong gross margin.
The company's strategic initiatives, including GenesisX and the APT acquisition, position it well for future growth and market expansion.
Analysts' inquiries reflect interest in key growth drivers like GenesisX, manufacturing scale-up, and macroeconomic influences on the business.
Overall, Stereotaxis Inc. aims for a stronger second half in 2024, leveraging new product offerings and revenue streams for improved financial performance.

Stereotaxis Inc reports revenue growth in Q3 2024 earnings

Stereotaxis Inc showed solid revenue growth in Q3 2024, driven by system and recurring revenue.
While facing challenges in operating expenses and profitability, the company has opportunities for growth.
Managing expenses and capitalizing on revenue potential could position Stereotaxis for improved financial performance.
The increase in cash reserves also provides a buffer for future investments and operations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ST. LOUIS, June  02, 2020  (GLOBE NEWSWIRE) --  Stereotaxis  (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has reached a significant milestone of over 400 scientific publications now documenting the clinical benefits of Stereotaxis robotic technology. A complete, searchable database of all publications is available online at  www.RoboticEP.com/Clinical-Data .

Stereotaxis Robotic Technology Now Referenced In Over 400 Scientific Publications

ST. LOUIS, May  26, 2020  (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with certain funds managed by Consonance Capital Management, a prominent healthcare-focused institutional investor. Stereotaxis is issuing approximately 3.66 million shares of registered common stock at a purchase price of $4.10 per share, for gross and net proceeds of approximately $15 million. The purchase price reflects a 9% premium to Stereotaxis’ 10-day volume-weighted average trading price.

Stereotaxis Announces $15 Million Common Stock Financing

Stereotaxis, Inc. (STXS) CEO David Fischel on Q1 2020 Results - Earnings Call Transcript

Stereotaxis, Inc. (STXS) CEO David Fischel on Q4 2019 Results - Earnings Call Transcript

ST. LOUIS, March  06, 2020  (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the  Genesis RMN® System  for the robotic navigation of magnetic ablation catheters to treat heart rhythm disorders.

Stereotaxis Earns FDA Clearance and Announces U.S. Launch of Genesis Robotic Magnetic Navigation System

Stereotaxis: A Small But Stellar Performer In The Medical Robotics Space

Stereotaxis: Poised For A Strong 2020

ST. LOUIS, Dec.  16, 2019  (GLOBE NEWSWIRE) --  Stereotaxis  (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that HCA Midwest Health—the largest healthcare system in the Kansas City region—has launched a new robotic arrhythmia care program based at Overland Park Regional Medical Center (OPRMC). Installation of the Stereotaxis  Robotic Magnetic Navigation (RMN)  System was recently completed, and the first patients have been successfully treated using the technology at  Overland Park Regional Medical Center .  Stereotaxis’ partnership with HCA Midwest Health brings new, leading-edge treatment options for patients who have a cardiac arrhythmia. The addition of RMN is a key component of the cardiology program at OPRMC and HCA Midwest Health, allowing for patient-focused clinical and technological leadership as well as enabling the providers and clinical team to better address a range of complex arrhythmias that otherwise might not have been treatable.  RMN uses robotics and magnetic fields to navigate a cardiac catheter directly from the tip. The technology consists of two robotically controlled magnets placed next to the operating table. During the procedure, a physician uses a computer interface to adjust the magnetic field around the patient and precisely direct and steer this cardiac ablation catheter in the heart.  Dr. Dhanunjaya “DJ” Lakkireddy, Medical Director, Kansas City Heart Rhythm Institute at HCA Midwest Health and a partner of Midwest Heart and Vascular Specialists, has been at the forefront of this technological innovation. Dr. Lakkireddy was instrumental in authoring the  meta-analysis  published in the Journal of Interventional Cardiac Electrophysiology (September 2017). The study emphasized the clinical value of robotics for the treatment of arrhythmias.  “The new cardiac arrhythmia labs at OPRMC were recently opened and are currently treating patients,” said Dr. Lakkireddy.  “They represent the latest advances in the field of electrophysiology including robotic technology that enables improved outcomes and unparalleled safety for patients during cardiac ablation procedures. Robotics also allows OPRMC electrophysiologists to better address a range of complex arrhythmias that otherwise might not have been treated, providing hope to many patients who otherwise would have had no options for cardiac arrhythmia. We have observed the clinical value of robotic cardiac ablation and are excited to be providing patients convenient access to this technology.”  “As a world-renowned leader in electrophysiology research and patient care, Dr. Lakkireddy recognizes the significant patient, provider, and physician benefits of RMN. Stereotaxis technology affords OPRMC increased capabilities and a new and novel way to treat patients with cardiac arrhythmias,” explained David Fischel, Chairman and Chief Executive Officer of Stereotaxis. “We look forward to supporting the Kansas City Heart Rhythm Institute and HCA Midwest Health as they improve patient care, advance clinical science, and grow a highly successful robotic arrhythmia care practice in Kansas City.”

First Patients Treated in New Robotic Arrhythmia Care Program at Overland Park Regional Medical Center

A series of financial missteps led to a delisting for Stereotaxis in 2013. Now that a new CEO has made some progress toward a turnaround, the robotic technology company may deserve a second chance.

Is It Time to Buy This Robotic Surgery Stock?

Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2019 Results - Earnings Call Transcript

ST. LOUIS and MT. OLIVE, N.J., Nov.  08, 2019  (GLOBE NEWSWIRE) --  Stereotaxis  (NYSE American: STXS) and  Catheter Precision  today announced the first patients have been successfully treated with the integration of Catheter Precision’s VIVO™ arrhythmia localization and Stereotaxis’ Robotic Magnetic Navigation technologies.

Stereotaxis and Catheter Precision Combine Robotic Navigation and Preoperative Arrhythmia Localization to Treat Cardiac Arrhythmias

ST. LOUIS and PESSAC, France, Nov.  05, 2019  (GLOBE NEWSWIRE) --  Stereotaxis  (NYSE American: STXS) and  inHEART  today announced the first patients have been successfully treated with the integration of inHEART’s advanced preoperative mapping and Stereotaxis’ Robotic Magnetic Navigation technologies.

Stereotaxis and inHEART Combine Robotic Precision and Advanced Preoperative 3D Mapping to Treat Cardiac Arrhythmias

ST. LOUIS and BARCELONA, Spain, Nov.  01, 2019  (GLOBE NEWSWIRE) --  Stereotaxis  (NYSE American: STXS) and  ADAS 3D Medical SL  today announced the first patients have been successfully treated with the integration of ADAS 3D’s advanced preoperative substrate mapping and Stereotaxis’  Robotic Magnetic Navigation  technologies.

Stereotaxis and ADAS 3D Combine Robotic Precision and Advanced Preoperative Substrate Mapping to Treat Cardiac Arrhythmias

Accuray

Intuitive Surgical

Medtronic

Stryker

Varian Medical Systems

Accuray and Stereotaxis are hyper-focused on growth.

High-Tech Robotic Surgery Gets Specialized

ST. LOUIS, Mo., Sept.  16, 2019  (GLOBE NEWSWIRE) --  Stereotaxis  (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer, effective October 1, 2019. Martin Stammer, who has served as Chief Financial Officer since 2013, has accepted a position as the CFO of a large professional services firm headquartered in the St. Louis area and will resign from the Company, effective September 30, 2019.

News for Stereotaxis Inc Stock (STXS)